<DOC>
	<DOCNO>NCT00192569</DOCNO>
	<brief_summary>Australian Trial Acute Hepatitis C ( ATAHC ) A prospective non-randomised dual arm longitudinal cohort newly acquire hepatitis C infection participant enrol follow 3 monthly interval 3 year period . All participant offer 24 week course pegylated interferon alfa 2a commence within 12 week screen ( patient coinfected HIV offer 24 week pegylated interferon alfa 2a plus ribavirin ) .</brief_summary>
	<brief_title>Australian Trial Acute Hepatitis C</brief_title>
	<detailed_description>The main purpose study : - To enrol follow-up large group people acute hepatitis C infection examine people naturally clear hepatitis C n't . - To examine many people become re-infected cleared hepatitis C look happen . The study also offer everyone take part option undergo 6 month course pegylated interferon alfa 2a ( plus ribavirin HIV coinfected ) treatment hepatitis C. The purpose part study : 1 . To examine whether treatment effective clearing virus .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient &gt; 16 year age ; AntiHCV antibody positive within previous 6 month ; AntiHCV antibody negative two year prior antiHCV antibody positive result OR acute hepatitis ( jaundice ALT &gt; 10 XULN ) within 12 month prior antiHCV antibody result ( cause acute hepatitis exclude ) ; HCV RNA positive ( treatment group ) ; Negative urine blood pregnancy test ( woman childbearing potential ; treat arm ) ; Informed consent Women ongoing pregnancy breast feeding ; Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) &lt; 6 month prior first dose study drug ; Any investigational drug &lt; 6 week prior first dose study drug ; Positive test screen antiHAV IgM Ab , antiHBc IgM Ab ; History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) ; History evidence bleed esophageal varix condition consistent decompensated liver disease ; Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screening ; Serum creatinine level &gt; 1.5 time upper limit normal screening ; Hgb &lt; 12g/dL woman &lt; 13g/dL men screen ( patient receive combination therapy Pegylated interferon ribavirin ) ; Male partner woman pregnant ( patient receive combination therapy Pegylated interferon ribavirin ) ; History severe seizure disorder current anticonvulsant use ; History immunologically mediate disease , chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , malignancy , condition would make patient , opinion investigator , unsuitable study ; History thyroid disease poorly control prescribed medication , elevate thyroid stimulate hormone ( TSH ) concentration elevation antibody thyroid peroxidase clinical manifestation thyroid disease ; Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) ; Inability unwillingness provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Acute Hepatitis C</keyword>
</DOC>